S&P 500   5,011.12
DOW   37,775.38
QQQ   423.41
What's Driving Tesla Lower Ahead of its Earnings?
Top 5 AI Stocks to Buy for 2024 (Ad)
Stock market today: Wall Street drifts to a mixed finish as yields tick higher
How major US stock indexes fared Thursday, 4/18/2024
The “Perfect Storm” for Gold (Ad)
3 Steel Stocks Could Soar on New China Tariffs
CSX Co.: The Railroad Powering Ahead with an Earnings Beat
How Biden has already won 2024 (Ad)
These are the Top 4 Stocks for Buybacks in 2024
'There is no time to waste': EU leaders want to boost competitiveness to close gap with US and China
S&P 500   5,011.12
DOW   37,775.38
QQQ   423.41
What's Driving Tesla Lower Ahead of its Earnings?
Top 5 AI Stocks to Buy for 2024 (Ad)
Stock market today: Wall Street drifts to a mixed finish as yields tick higher
How major US stock indexes fared Thursday, 4/18/2024
The “Perfect Storm” for Gold (Ad)
3 Steel Stocks Could Soar on New China Tariffs
CSX Co.: The Railroad Powering Ahead with an Earnings Beat
How Biden has already won 2024 (Ad)
These are the Top 4 Stocks for Buybacks in 2024
'There is no time to waste': EU leaders want to boost competitiveness to close gap with US and China
S&P 500   5,011.12
DOW   37,775.38
QQQ   423.41
What's Driving Tesla Lower Ahead of its Earnings?
Top 5 AI Stocks to Buy for 2024 (Ad)
Stock market today: Wall Street drifts to a mixed finish as yields tick higher
How major US stock indexes fared Thursday, 4/18/2024
The “Perfect Storm” for Gold (Ad)
3 Steel Stocks Could Soar on New China Tariffs
CSX Co.: The Railroad Powering Ahead with an Earnings Beat
How Biden has already won 2024 (Ad)
These are the Top 4 Stocks for Buybacks in 2024
'There is no time to waste': EU leaders want to boost competitiveness to close gap with US and China
S&P 500   5,011.12
DOW   37,775.38
QQQ   423.41
What's Driving Tesla Lower Ahead of its Earnings?
Top 5 AI Stocks to Buy for 2024 (Ad)
Stock market today: Wall Street drifts to a mixed finish as yields tick higher
How major US stock indexes fared Thursday, 4/18/2024
The “Perfect Storm” for Gold (Ad)
3 Steel Stocks Could Soar on New China Tariffs
CSX Co.: The Railroad Powering Ahead with an Earnings Beat
How Biden has already won 2024 (Ad)
These are the Top 4 Stocks for Buybacks in 2024
'There is no time to waste': EU leaders want to boost competitiveness to close gap with US and China
Free Trial
ASX:ATX

Amplia Therapeutics (ATX) Stock Price, News & Analysis

→ Biden’s $374B Giveaway Into This Sector (From DTI) (Ad)
Free ATX Stock Alerts
Compare
Today's Range
N/A
50-Day Range
N/A
52-Week Range
N/A
Volume
77,249 shs
Average Volume
N/A
Market Capitalization
N/A
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Stock Analysis
Stock Analysis

About Amplia Therapeutics

Amplia Therapeutics Limited, a pharmaceutical company, focuses on development of focal adhesion kinase (FAK) inhibitors for cancer and fibrosis in Australia. The company's product pipeline includes AMP945, an inhibitor of FAK, for pancreatic cancer and idiopathic pulmonary fibrosis, as well as other solid tumors and fibrotic diseases indications, that has completed Phase I clinical trial; and AMP886 for acute myeloid leukemia (AML) and certain solid tumors.It has a collaboration agreement with the Garvan Institute of Media Research in Sydney. The company was formerly known as Innate Immunotherapeutics Limited and changed its name to Amplia Therapeutics Limited in September 2018. Amplia Therapeutics Limited was incorporated in 2000 and is headquartered in Melbourne, Australia.

ATX Stock News Headlines

February 14, 2024 | finance.yahoo.com
Amplia Therapeutics moves to next phase of pancreatic cancer treatment trial
January 18, 2024 | finance.yahoo.com
FDA CLEARANCE OF AMPLIA'S IND FOR PANCREATIC CANCER TRIAL IN US
April 18, 2024 | DTI (Ad)
Biden’s $374B Giveaway Into This Sector
Biden’s Climate Bill Could Send Your Retirement Accounts Soaring – Or Diving See what this $374B giveaway could mean for your retirement right here
August 22, 2023 | seekingalpha.com
GDTC CytoMed Therapeutics Limited
May 29, 2023 | finance.yahoo.com
AMP945 Combined with FOLFIRINOX Enhances Treatment Effects in model of Pancreatic Cancer
May 22, 2023 | proactiveinvestors.com.au
Amplia secures funding to assess AMP945 topical applications
May 17, 2023 | investing.com
Amplia Therapeutics Ltd (ATX)
March 10, 2023 | uk.finance.yahoo.com
Amplia Therapeutics Limited (ATX.AX)
April 18, 2024 | DTI (Ad)
Biden’s $374B Giveaway Into This Sector
Biden’s Climate Bill Could Send Your Retirement Accounts Soaring – Or Diving See what this $374B giveaway could mean for your retirement right here
February 27, 2023 | finance.yahoo.com
Amplia Therapeutics CEO outlines 2023 milestones
See More Headlines
Receive ATX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Amplia Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange
ASX
Sector
Medical
Industry
Biotechnology
Sub-Industry
N/A
Current Symbol
ASX:ATX
CUSIP
N/A
CIK
N/A
Web
www.ampliatx.com
Phone
61 2 8003 3650
Fax
N/A
Employees
N/A
Year Founded
N/A

Profitability

EPS (Most Recent Fiscal Year)
A($0.02)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-4,460,000.00
Net Margins
-238.69%
Pretax Margin
N/A
Return on Equity
-26.40%
Return on Assets
-14.40%

Debt

Debt-to-Equity Ratio
15.18
Current Ratio
3.43
Quick Ratio
5.05

Sales & Book Value

Annual Sales
$1.87 million
Price / Sales
0.00
Cash Flow
N/A
Price / Cash Flow
4.88
Book Value
A$0.08 per share
Price / Book
N/A

Miscellaneous

Outstanding Shares
194,010,000
Free Float
N/A
Market Cap
N/A
Optionable
Not Optionable
Beta
0.51
7 AI Stocks to Invest In: An Introduction to AI Investing For Self-Directed Investors Cover
7 AI Stocks to Invest In: An Introduction to AI Investing For Self-Directed Investors

As the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.

Get This Free Report

Key Executives

  • Dr. Christopher J. Burns B.Sc. (Age 59)
    BSc(Hons), Ph.D., CEO, MD & Director
    Comp: $1.51M
  • Mr. Tim Luscombe B.Com.
    C.A., Chief Financial Officer
  • Ms. Rhiannon Jones B.Sc.
    Ph.D., Chief Operating Officer
  • Mr. Andrew John Cooke FAICS (Age 64)
    FCIS, FGIA, L.L.B., LLB, MAICD, Company Secretary
    Comp: $76.67k

Key Competitors

View All Competitors

Insiders


This page (ASX:ATX) was last updated on 4/18/2024 by MarketBeat.com Staff

From Our Partners
SHOCKING Crypto Leak…
Crypto 101 Media
The Best AI Stock to Own in the World Today is Trading for Just $25
Banyan Hill Publishing
Biden’s $374B Giveaway Into This Sector
DTI
The “Perfect Storm” for Gold
Gold Safe Exchange
Biden replacement revealed?
Paradigm Press
The #1 Crypto for 2024
InvestorPlace
Did You Get Your Free Bitcoin Yet?
Crypto Swap Profits
Top 5 AI Stocks to Buy for 2024
Market Moving Trends